Publication date: Nov 06, 2019
This review describes the evolving role of surgery in stage III and IV melanoma.
Surgery has been the first option to cure melanoma patients at initial diagnosis of metastatic spread: a complete surgical excision of the disease either in stage III or IV has been the gold standard for decades. A positive sentinel node biopsy (SNB) has been followed by a complete lymph node dissection (CLND) since the early stages of modern surgical oncology. However, since two randomized trials have indicated that a CLND does not improve survival in patients with a positive SNB, a CLND is no longer considered mandatory. A therapeutic lymph node dissection (TLND) is still offered to patients with macroscopic nodal disease and in highly selected cases, patients with distant melanoma metastases can be treated surgically as well. Also the availability of adjuvant, and in the future possibly neoadjuvant, systemic therapy have shifted the landscape to less extensive surgery in metastatic melanoma. With the development of new systemic options, surgery in metastatic melanoma has become more and more part of a multidisciplinary treatment: surgical indications are moving from previous standards to a new role.
Testori, A.A.E., Blankenstein, S.A., and van Akkooi, A.C.J. Surgery for Metastatic Melanoma: an Evolving Concept. 24687. 2019 Curr Oncol Rep (21):11.
- [Sentinel node biopsy and lymph node dissection in the era of new systemic therapies for malignant melanoma].
- Current management of patients with melanoma who are found to be sentinel node-positive.
- Updates in Melanoma by Yiyi Yan, M.D., Ph.D. | Preview
- Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma